세계의 동물용 재생의료 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Veterinary Regenerative Medicine Market was valued at USD 344.9 million in 2024 and is estimated to grow at a CAGR of 12.3% to reach USD 1.1 billion by 2034. This growth is being fueled by a rising pet population, a growing awareness of innovative veterinary treatment options, and a steady increase in chronic and degenerative conditions among companion animals. As pet owners continue to prioritize high-quality healthcare for their animals, the demand for regenerative therapies like stem cell treatment and platelet-rich plasma therapy is gaining traction. Veterinarians are increasingly turning to these therapies to address pain, inflammation, and tissue repair in aging pets and animals with injuries. Regenerative medicine is also becoming more accessible thanks to strong financial support from both public and private institutions. With ongoing breakthroughs in biotechnology and supportive clinical evidence, the adoption of regenerative approaches is expanding rapidly across veterinary clinics worldwide. The shift toward minimally invasive and long-lasting treatment options is changing how chronic pain, musculoskeletal injuries, and degenerative disorders are being managed in veterinary practices.

The dog segment alone generated USD 225.6 million in 2024 and is expected to reach USD 701.8 million by 2034, signaling robust demand for therapies that target common issues like ligament injuries, arthritis, and joint degeneration. As dogs age, they're more susceptible to musculoskeletal complications, prompting both pet owners and veterinarians to seek advanced solutions that enhance mobility and reduce pain. Treatments such as tissue engineering, stem cell therapies, and platelet-rich plasma are proving especially effective in restoring function and improving quality of life for canine patients. The trend is pushing clinics to integrate regenerative medicine into routine care for aging or injured dogs.

By product category, stem cell therapy accounted for a dominant 52.1% market share in 2024. This segment continues to thrive due to its proven ability to promote tissue regeneration, minimize inflammation, and accelerate recovery. The industry is witnessing rapid development in both autologous and allogeneic stem cell applications, driven by increasing veterinary clinical trials and broader therapeutic use. These advances are making stem cell therapy one of the most promising and widely accepted treatment modalities in animal care, particularly for dogs and horses.

The U.S. Veterinary Regenerative Medicine Market brought in USD 97.8 million in 2024, backed by cutting-edge healthcare infrastructure, a high rate of pet adoption, and a growing number of animals suffering from joint and muscular disorders. The presence of leading industry players, rising R&D investments, and wider availability of specialized regenerative services have further strengthened the country's market position. Supportive regulatory initiatives and innovation-focused grants are also playing a key role in driving domestic growth.

To capture greater market share, key players such as Vetherapy, Animal Cell Therapies, Cell Therapy Sciences, VetStem, Lynch Biologics, Boehringer Ingelheim International, Dechra Pharmaceuticals, Regen Lab, Magellan Stem Cells, Enso Discoveries, Ardent, EquiCord, and Medrego are doubling down on product innovation and strategic research partnerships. Companies are ramping up clinical trials, investing in next-gen biologics, and developing scalable regenerative therapies. Partnerships with veterinary clinics, educational outreach, and global distribution strategies remain central to meeting growing demand and reinforcing market presence.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and degenerative conditions
    • 3.2.1.2 Growing advancement in regenerative medicine
    • 3.2.1.3 Increasing research and development investments
    • 3.2.1.4 Growing pet ownership and healthcare spending
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Treatment-related adverse effects
    • 3.2.2.2 Regulatory compliance challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Pet population by country
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell therapy
  • 6.2.1 Autologous
  • 6.2.2 Allogeneic
• 6.3 Biological therapy
  • 6.3.1 Platelet-rich plasma (PRP)
  • 6.3.2 Growth factor
• 6.4 Tissue engineering

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Orthopedics
• 7.3 Trauma/ wound care
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Academics and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Animal Cell Therapies
• 10.2 Ardent
• 10.3 Boehringer Ingelheim International
• 10.4 Cell Therapy Sciences
• 10.5 Dechra Pharmaceuticals
• 10.6 Enso Discoveries
• 10.7 EquiCord
• 10.8 Lynch Biologics
• 10.9 Magellan Stem Cells
• 10.10 Medrego
• 10.11 Regen Lab
• 10.12 Vetherapy
• 10.13 VetStem